Goldman Sachs put out a new research report this week which asks the question “pharma versus biotech: which is cheaper?” Since the start of the great healthcare bull run, which began during 2011, healthcare earnings multiples have risen from 12 times earnings, to 17.6 times earnings and the sector now trades at a slight premium to the S&P 500. The S&P 500 trades at a P/E of 17 according to Goldman’s data. But not all healthcare sectors are created equal. For example, at the bottom of the scale, the managed care sector trades at a P/E of 16.6. While at…
Goldman Sachs – Pharma Versus Biotech Valuation
Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk
Comments are closed.